Androgen abuse in the community

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 3, 2009, Pages 218-223

  Melnik, Bodo C ^a,b  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

^b NONE   (Germany)

Author keywords

Acne; Anabolic androgenic steroids; Androgen; Androgen epidemic; Chronic toxicity; Health risk

Indexed keywords

ANDROGEN; GROWTH HORMONE; INSULIN; MILK PROTEIN;

CHRONIC TOXICITY; DRUG ABUSE; GERMANY; HEALTH CARE; HEALTH CENTER; HEALTH HAZARD; HUMAN; LEISURE; MIDDLE AGED; PHYSICAL ATTRACTIVENESS; PREVALENCE; PUBLIC HEALTH PROBLEM; REVIEW; SEX DIFFERENCE; SPORT; ADDICTION; ADOLESCENT; ADULT; BEVERAGE; COMMUNITY CARE; DIET SUPPLEMENTATION; DOPING; FEMALE; INTERNET; MALE; PUBLIC HEALTH; RISK ASSESSMENT;

ADOLESCENT; ADULT; ANDROGENS; BEVERAGES; COMMUNITY HEALTH SERVICES; DIETARY SUPPLEMENTS; DOPING IN SPORTS; FEMALE; FITNESS CENTERS; GROWTH HORMONE; HUMANS; INSULIN; INTERNET; MALE; MIDDLE AGED; MILK PROTEINS; PREVALENCE; PUBLIC HEALTH; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 66349118404     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32832afdfe     Document Type: Review

References (64)

1. Pope H, Brower K. Ananbolic-androgenic steroid abuse. In: Sadock B, Sadock V, editors. Comprehensive textbook of psychiatry. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2005. pp. 1318-1328.
2. Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol 2004; 4:614-620.
3. Smurawa TM, Congeni JA. Testosterone precursors: use and abuse in pediatric athletes. Pediatr Clin N Am 2007; 54:787-796. (Pubitemid 47307357)
4. Sheffield-Moore M, Urban RJ. An overview of the endocrinology of skeletal muscle. Trends Endocrinol Metabol 2004; 15:110-115.
5. Kanayama G, Gruber AJ, Pope HG Jr, et al. Over-the counter drug use in gymnasiums: an underrecognized substance abuse problem? Psychother Psychosom 2001; 70:137-140.
6. Kanayama G, Pope HG Jr, Cohane G, et al. Risk factors for anabolic-androgenic steroid use among weight-lifters: a case control study. Drug Alcohol Depend 2003; 71:77-86. (Pubitemid 36734861)
7. Komorowski EM, Rickert VI. Adolescent body image and attitudes to anabolic steroid use. Am J Dis Child 1992; 146:823-828.
8. Kerr JM, Congeni JA. Anabolic-androgenic steroids: use and abuse in pediatric patients. Pediatr Clin N Am 2007; 54:771-785. An enhanced understanding of AAS and the motivation behind their abuse in pediatric patients.
9. Fitch KD. Androgenic-anabolic steroids and the Olympic Games. Asian J Androl 2008; 10:384-390.
10. Wade N. Anabolic steroids: doctors denounce them, but athletes aren't listening. Science 1972; 176:1399-1403.
11. Kammerer RC. Drug testing and anabolic steroids. In: Yesalis CE, editor. Anabolic steroids in sport and exercise. Champaign, Illinois, USA: Human Kinetics; 2000. pp. 415-459.
12. Pope Jr HG, Phillips K, Olivardia R. The Adonis complex: the secret crisis of male body obsession. New York, USA: Simon & Shuster; 2000.
13. Duchaine D. The original underground steroid handbook. Venice, California, USA: OEM Media; 1981.
14. Phillips WN. Anabolic reference guide. 1st ed. Golden, Colorado, USA: Mile High Publishing; 1985.
15. Buckley WE, Yesalis CE III, Friedl KE, et al. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988; 260:3441-3445.
16. Hoberman J. Testosterone dreams: rejuvenation, aphrodisia, doping. Berkeley, California, USA: University of California Press; 2005.
17. Johnson MD, Jay MS, Shoup B, Rickert VI. Anabolic steroid use by male adolescents. Pediatrics 1989; 83:921-924. (Pubitemid 19154660)
18. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975-2005. In: College students and adults ages 19-45, vol.II. NIH publication no. 06-5884. Bethesda, Maryland, USA: National Institute on Drug Abuse; 2006.
19. SAMHSA. National Survey on Drug Use and Health (formerly called the National Household Survey); 1991. http://www.icpsr.umich.edu/cgibin/SDA/SAMHDA/ hsda?samhda+06128-0001.
20. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. JAMA 1993; 270:1217-1221. (Pubitemid 23262352)
21. Johnston LD, O'Malley PM, Bachman JG. Monitoring the future national survey results on drug use, 1975-2002. Vol.1. Secondary school students (NIH publication no. 03-5375). Bethesda, Maryland, USA: National Institute on Drug Abuse; 2003.
22. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance: United States, 2005. MMWR Surveill Summ 2006; 55:1-108.
23. Williamson DJ. Anabolic steroid use among students at a British college of technology. Br J Sports Med 1993; 27:200-201.
24. Schwellnus MP, Lambert MI, Todd MP, Juritz JM. Androgenic anabolic steroid use in matric pupils. A survey of prevalence of use in the western Cape. S Afr Med J 1992; 82:154-158.
25. Nilsson S. Androgenic anabolic steroid use among male adolescents in Falkenberg. Eur J Clin Pharmacol 1995; 48:9-11.
26. Handelsman DJ, Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int J Androl 1997; 20:159-164. (Pubitemid 27470087)
27. Rachón D, Pokrywka L, Suchecka-Rachón K. Prevalence and risk factors of anabolic steroids (AAS) abuse among adolescents and young adults in Poland. Soz Praventivmed 2006; 51:392-398. (Pubitemid 44873623)
28. Nilsson S, Baigi A, Marklund B, Fridlund B. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health 2001; 11:195-197. (Pubitemid 32606539)
29. Nilsson S, Spak F, Marklund B, et al. Attitudes and behaviors with regards to androgenic anabolic steroids among male adolescents in a county of Sweden. Subst Use Misuse 2005; 40:1-12. (Pubitemid 39166944)
30. Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam Clin Pharmacol 2005; 19:27-44. (Pubitemid 40204345)
31. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006; 38:644-651.
32. Wood RI. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol 2008; 29:490-506. A recent evidence linking AAS with opioids with special attention to common neurotransmitter systems involved in AAS dependence.
33. Boos C, Wulff P, Kujath P, et al. Drug abuse in leisure sports. Dtsch Ärztebl 1998; 95:A953-957.
34. Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the healthcare system. Drug Alcohol Depend 2006; 81:11-19. (Pubitemid 41682474)
35. Simon P, Striegel H, Aust F, et al. Doping in fitness sports: estimated number of unreported cases and individual probability of doping. Addiction 2006; 101:1640-1644. (Pubitemid 44527196)
36. Graham MR, Evans P, Davies B, Baker JS. AAS, growth hormone, and insulin abuse: psychological and neuroendocrine effects. Ther Clin Risk Manage 2008; 4:587-597. Important new information concerning the combined abuse of AAS with insulin and recombinant growth hormone. (Pubitemid 352037898)
37. Baker JS, Graham MR, Davies B. 'Steroid' and prescription medicine abuse in the health and fitness community; a regional study. Eur J Intern Med 2006; 17:479-484.
38. Grace FM, Baker JS, Davies B. Anabolic androgenic steroid (AAS) use in recreational gym users: a regional sample of the Mid-Glamorgan area. J Subst Use 2001; 12:145-153. (Pubitemid 33040341)
39. Wanjek B, Rosendahl J, Strauss B, Gabriel HH. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med 2007; 28:346-353. (Pubitemid 46640303)
40. Skarberg K, Nyberg F, Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur Addict Res 2009; 15:99-106.
41. Eklöf AC, Thurelius AM, Garle M, et al. The antidoping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol 2003; 59:571-577. (Pubitemid 37494522)
42. Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges 2007; 5:110-117. (Pubitemid 46212727)
43. Melnik B. Milk consumption: aggravating factor of acne and promoter of chronic diseases of Western societies. J Dtsch Dermatol Ges 2009. [Epub ahead of print]
44. Denley A, Cosgrove LJ, Booker GW, et al. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005; 16:421-439.
45. Rosignoli C, Nicolas JC, Jomard A, et al. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Exp Dermatol 2003; 12:480-489. (Pubitemid 36992424)
46. Smith TM, Cong Z, Gilliland KL, et al. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol 2006; 126:1226-1232. (Pubitemid 43997901)
47. Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in adolescent girls. Dermatology Online J 2006; 12:1-12. (Pubitemid 43920199)
48. Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in teenaged boys. J Am Acad Dermatol 2008; 58:787-793.
49. Östman EM, Liljeberg Elmstahl HGM, Björck IME. Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. Am J Clin Nutr 2001; 74:96-100.
50. Hoyt G, Hickey MS, Cordain L. Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. Br J Nutr 2005; 93:175-177.
51. Hoppe C, Molgaard C, Michaelsen KF. Cow's milk and linear growth in industrialized and developing countries. Annu Rev Nutr 2006; 26:131-173.
52. Melnik BC. Milk: the promoter of chronic western diseases. Med Hypotheses 2009. [Epub ahead of print] New insights into the interrelationship between abuse of AAS, insulin, and growth hormone and the synergistic insulinotrophic effects of milk consumption on the development of chronic western diseases.
53. Kanayama G, Hudson JI, Pope HG Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend 2008; 98:1-12. Information about the long-term medical consequences of AAS abuse of former AAS abusers now moving into middle age.
54. Marshall-Gradisnik S, Green R, Brenu EW, Weatherby RP. Anabolic androgenic steroids effects on the immune system: a review. Cent Eur J Biol 2009; 4:19-33.
55. Beaver KM, Vaughn MG, DeLisi M, Wright JP. Anabolic-androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the United States. Am J Public Health 2008; 98:2185-2187.
56. Nilsson S. Misuse of anabolic steroids in youth: trends, attitudes and evaluation of an intervention programme [PhD thesis]. Gothenburg, Sweden: University of Gothenburg; 2003.
57. Goldberg L, McKinnon DP, Elliot DL, et al. The adolescents training and learning to avoid steroids program. Preventing drug use and promoting health behaviors. Arch Pediatr Adolesc Med 2000; 154:332-338.
58. Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008; 371:1872-1882. Most recent review of prevalence of AAS misuse, adverse effects, and long-term consequences of AAS abuse for society. (Pubitemid 351734542)
59. Di Luigi L, Romanelli F, Lenzi A. Androgenic-anabolic steroids abuse in males. J Endocrinol Invest 2005; 28 (3 Suppl):81-84.
60. Graham MR, Davies B, Grace FM, et al. Anabolic steroid use: patterns of use and detection of doping. Sports Med 2008; 38:505-525. (Pubitemid 351704855)
61. Rodriguez-Gonzales G, Ramirez-Moreno R, Perez P, et al. The GGN and CAG repeat polymorphisms in the exon-1 of the androgen receptor gene are, respectively, associated with insulin resistance in men and with dyslipidemia in women. J Steroid Biochem Mol Biol 2009; 113:202-208.
62. Boyd DB. Insulin and cancer. Integr Cancer Ther 2003; 2:315-329.
63. Fürstenberger G, Senn H-J. Insulin-like growth factors and cancer. Lancet 2002; 3:298-302.
64. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev 2007; 6:821-833. Most interesting review on the consequences of increased insulin/IGF-1-mediated signal transduction in the pathogenesis of chronic western diseases and new avenues for pharmacological intervention.